Progress in Medicinal Chemistry: Volume 63

About

Jonathan Bentley is a VP Scientific Director at Evotec in the Discovery Chemistry department in Abingdon UK. He is responsible for the scientific strategy on multiple collaborations and provides strategic leadership and support for scientific delivery across multi-disciplinary drug discovery programs. Within Evotec he leads the cross-functional global Design Evolution initiative. He joined Evotec as a Project Leader in 2007 and was promoted to VP in 2020. Prior to Evotec he was a Research Leader at the Psychiatry Centre of Excellence in Drug Design for GSK Verona for 3.5 years after spending the formative phase of his industrial career at Vernalis in Reading UK for 7 years. He has contributed to the identification of multiple clinical and preclinical candidates as project leader or as part of multidisciplinary drug discovery teams in collaboration with international scientific and strategic partners. He has a PhD in Synthetic Organic Chemistry from the University of Bristol sponsored by SmithKline Beecham (1995). He spent a year in a post-doctoral position at University of Cape Town supported by Schering AG (1995-6). He has worked on projects across many different therapeutic areas including Oncology Inflammation Pain CNS (Anxiety Depression Drug Dependence Schizophrenia Insomnia Neurodegeneration) Metabolic Diseases and Womens Health. He has enjoyed working on multiple target classes including agonists antagonists PAMs and NAMs of GPCRs from all classes diverse enzyme inhibitors and activators and ion channel blockers openers and modulators as well as phenotypic endpoints. He was the first recipient of the RSC / SCI Capps-Green-Zomaya award in 2004. Tilly (Matilda) Bingham is a drug discoverer with over 20 years experience of working in the pharmaceutical R&D sector in large pharma (Organon Schering-Plough MSD) Biotech (Redx Pharma) CRO (Concept Life Sciences) and is currently Executive in Residence at Cumulus Oncology. Tillys early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R V1R and CGRP. Then as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates including the clinical candidate porcupine inhibitors RXC004 (oncology) RXC006 (AZD5055 fibrosis) Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points.